{"entity":{"id":"trop2","kind":"target","name":"TROP2","aka":[],"tldr":"TROP2 is a surface glycoprotein present at high levels on most epithelial cancers (breast, lung, urothelial, gastric, pancreatic) and at low levels on normal tissue. It does not drive the cancer; it is a delivery address, used by the approved ADCs sacituzumab govitecan and datopotamab deruxtecan and by sacituzumab tirumotecan, with a TROP2 PET tracer in development to pick patients.","summary":"Trophoblast cell-surface antigen 2 is a transmembrane glycoprotein overexpressed in most epithelial cancers (breast, lung, urothelial, gastric, pancreatic) with low normal-tissue expression. It is not an oncogenic driver; it is a delivery address. Three TROP2 ADCs are approved or in registration (sacituzumab govitecan, datopotamab deruxtecan, sacituzumab tirumotecan) and a TROP2 PET tracer is in development to select patients.","asOf":"2026-09-04","links":[{"label":"UniProt P09758: TACSTD2 (TROP2)","url":"https://www.uniprot.org/uniprotkb/P09758/entry"}],"tags":["adc-target","pet-target"],"related":[],"indications":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"symbol":"TACSTD2","hgnc":"HGNC:11530","ensembl":"ENSG00000184292","uniprot":"P09758","entrez":"4070","biology":"Regulates calcium signalling and cell adhesion; overexpression correlates with poor prognosis. Expression is heterogeneous within tumours, which limits the value of IHC selection. Internalises on antibody binding and traffics to lysosomes, which is what makes it a good ADC target.","whereFound":["Triple-negative breast cancer (~80-90% express)","HR+ breast cancer","NSCLC","Urothelial carcinoma","Gastric, pancreatic, endometrial cancers"],"targetClass":"surface-antigen","prevalence":[]},"route":"/targets/trop2/","neighbours":{"technology":[{"id":"immuno-pet","kind":"technology","name":"Immuno-PET","route":"/technologies/immuno-pet/"},{"id":"trop2-pet","kind":"technology","name":"TROP2 PET","route":"/technologies/trop2-pet/"}],"institution":[{"id":"fuscc","kind":"institution","name":"Fudan University Shanghai Cancer Center","route":"/institutions/fuscc/"}],"term":[{"id":"antigen","kind":"term","name":"Antigen","route":"/terms/antigen/"}],"idea":[{"id":"idea-alpha-after-adc","kind":"idea","name":"Alpha radioligands after ADC failure","route":"/ideas/idea-alpha-after-adc/"},{"id":"idea-trop2-pet-selection","kind":"idea","name":"TROP2 PET to choose and sequence TROP2 ADCs","route":"/ideas/idea-trop2-pet-selection/"}],"person":[{"id":"song-shaoli","kind":"person","name":"Shaoli Song","route":"/people/song-shaoli/"}],"indication":[{"id":"breast-triple-negative","kind":"indication","name":"Triple-negative breast cancer","route":"/indications/breast-triple-negative/"}],"opportunity":[{"id":"opp-trop2-imaging-heterogeneity","kind":"opportunity","name":"TROP2 imaging where no tissue test is required","route":"/opportunities/opp-trop2-imaging-heterogeneity/"}],"target":[{"id":"tpbg-5t4","kind":"target","name":"5T4 (trophoblast glycoprotein)","route":"/targets/tpbg-5t4/"}]}}